Prenetics Global (NASDAQ:PRE) Shares Down 1.6% – Time to Sell?

Prenetics Global Limited (NASDAQ:PRE) shares dropped 1.6% on Friday . The stock traded as low as $5.70 and last traded at $5.70. Approximately 1,032 shares were traded during mid-day trading, a decline of 98% from the average daily volume of 48,158 shares. The stock had previously closed at $5.79.

Analyst Ratings Changes

Separately, Cantor Fitzgerald reiterated an “overweight” rating and set a $9.00 target price on shares of Prenetics Global in a research report on Wednesday, December 4th.

Prenetics Global Stock Performance

The stock has a 50-day simple moving average of $4.88 and a 200 day simple moving average of $5.12. The stock has a market capitalization of $52.08 million, a P/E ratio of -1.43 and a beta of -0.18.

Prenetics Global (NASDAQ:PRE) last posted its quarterly earnings results on Monday, October 7th. The company reported ($0.88) earnings per share (EPS) for the quarter. The firm had revenue of $5.94 million during the quarter. Prenetics Global had a negative net margin of 191.73% and a negative return on equity of 16.45%. Equities analysts predict that Prenetics Global Limited will post -3.3 earnings per share for the current year.

About Prenetics Global

Prenetics Global Limited, a genomics-driven health sciences company, engages in revolutionizing prevention, early detection, and treatment. It offers CircleDNA, a prevention arm that uses whole exome sequencing to offer comprehensive consumer DNA test. The company also, through its joint venture, Insighta, engages in pioneering multi-cancer early detection technologies.